You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

170 Results
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
May 2025
Drug
Other Name(s): Elrexfio™
Sep 2025
Document
New
Nov 2025
Document
Document
New
Nov 2025
Document
New
Nov 2025
Document
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    exemestane
New
Dec 2025

Pages